Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2018 | Initial data for CAR T-cell product JCAR021 in ALL and B-cell lymphoma

Jordan Gauthier • 2 Dec 2018
ASH 2018
Acute Lymphoblastic Leukemia B-Cell Lymphoma Leukemia Lymphoma Non-Hodgkin Lymphoma CAR-T JCAR021

Jordan Gauthier, MD, of the Fred Hutchinson Cancer Research Center, Seattle, WA, covers the data for JCAR021, bearing a human CD19-binding single chain variable fragment, for relapsed/refractory acute lymphoblastic leukemia (ALL) and B-cell lymphoma (NCT03103971). This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Jordan Gauthier

Relationship between IL-15 serum concentrations & CD19 CAR T-cell therapy 3:40
Relationship between IL-15 serum concentrations & CD19 CAR T-cell therapy
Jordan Gauthier • 28 Jan 2021
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies 3:23
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
IACH webinar: continuing the CAR-T discussion amid COVID-19 1:46
IACH webinar: continuing the CAR-T discussion amid COVID-19
Jordan Gauthier • 30 Mar 2020
CLL outcomes after CD19 CAR-T with ibrutinib 3:50
CLL outcomes after CD19 CAR-T with ibrutinib
Jordan Gauthier • 30 Mar 2020

Related Videos

Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas 1:57
Preliminary findings from a trial of a novel CD30-directed antibody-drug conjugate in R/R lymphomas
Swetha Thiruvengadam • 8 Dec 2025
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL 1:14
Interim analysis of a Phase II trial of epcoritamab plus lenalidomide in treatment-naive FL
Swetha Thiruvengadam • 8 Dec 2025
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL 3:07
Primary Phase III results from the EPCORE FL-1 trial: epcoritamab plus R2 versus R2 for R/R FL
Lorenzo Falchi • 6 Dec 2025
The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL 1:41
The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL
Pere Barba • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals